Logo image
Back
Poster Abstract #14: Magnetic Resonance Disease Severity Scale (MRDSS) Predicts Clinical Progression in Multiple Sclerosis
Abstract   Open access   Peer reviewed

Poster Abstract #14: Magnetic Resonance Disease Severity Scale (MRDSS) Predicts Clinical Progression in Multiple Sclerosis

Rohit Bakshi, Mohit Neema, Brian C. Healy, Zsuzsanna Liptak, Rebecca A. Betensky, Guy J. Buckle, Susan A. Gauthier, James Stankiewicz, Dominik Meier, Svetlana Egorova, …
Neurotherapeutics, Vol.5(3), pp.495-495
07/2008
DOI: 10.1016/j.nurt.2008.03.015
url
https://doi.org/10.1016/j.nurt.2008.03.015View
Published (Version of record) Open Access

Abstract

Combine MRI measures of disease severity into a composite score in patients with multiple sclerosis (MS). Brain MRI lesion and atrophy measures assessed individually have fairly weak ability to predict clinical progression in MS. In the Comprehensive Longitudinal Investigation of MS at Brigham, we studied 103 patients [age (mean ± SD) 42.7 ± 9.1 years, disease duration 14.1 ± 9.2 years, Expanded Disability Status Scale (EDSS) score 3.3 ± 2.2, 60% ( n = 62) relapsing–remitting (RR), 32% ( n = 33) secondary progressive (SP), and 8% ( n = 8) primary progressive]. Brain MRI measures included baseline T2 hyperintense (T2LV) and T1 hypointense (T1LV) lesion volume, and brain parenchymal fraction (BPF), a marker of global atrophy. The ratio of T1LV to T2LV assessed lesion severity. A Magnetic Resonance Disease Severity Scale (MRDSS) score, on a continuous scale from 0 to 10, was derived for each patient using T2LV, BPF, and T1/T2 ratio. MRDSS score averaged 5.1 ± 2.6. Baseline MRI and EDSS correlations were moderate for BPF, T1/T2, and MRDSS and weak for T2LV. MRDSS showed a larger effect size than any of the individual MRI components in distinguishing RR from SP patients. Models containing either T2LV or MRDSS were significantly associated with EDSS disability progression during the 3.2 ± 0.3 year observation period, when adjusting for baseline EDSS score. These results show that combining brain MRI lesion and atrophy measures can predict clinical progression in patients with MS and provide the basis to develop an MRI-based continuous scale as a marker of MS disease severity.

Details

Metrics

5 Record Views
Logo image